Bisphosphonates: A Dual Benefit in Breast Cancer?
Links shared publicly online about this topic.
- 1,304total visits
Bisphosphonates: A Dual Benefit in Breast Cancer?
View full resource at pharmacypracticenews.com
Tags: Breast Cancer, Women's Health, Antibiotic, Pharmacy Professions, Pharmacist, Oncology, Hemotology, Trauma
Most Recently Shared on March 19, 2010 at 9:08 am By:
Bisphosphonates: A Dual Benefit in Breast Cancer? http://shar.es/mWBoM
Dual agent therapy has positive effect on metastatic HER-2 breast cancer - News
virtualmedicalcentre.com — “Combination therapy benefits more than a third of women in study.” View full resource at virtualmedicalcentre.com
Most Recently Shared on July 28, 2011 at 2:03 pm By:
VirtualMedicalCentre Health Site
Dual agent therapy has positive effect on metastatic HER-2 breast cancer http://dlvr.it/cwY1c #Healthnews
Drug's benefit to younger breast cancer patients in question - latimes.com
latimes.com — “The bisphosphonate zoledronic acid did not improve survival rates for patients with early stage breast cancer except among women who were five or more years past menopause, a study finds.” View full resource at latimes.com
Most Recently Shared on December 10, 2010 at 1:08 am By:
Drug's benefit to younger breast cancer patients in question http://lat.ms/fqIUu5
Medical News: SABCS: Bone Drug Fails to Stop Breast Cancer - in Meeting Coverage, SABCS from MedPage Today
medpagetoday.com — “SAN ANTONIO -- Women with stage II/III breast cancer derived no survival benefit when the bisphosphonate zoledronic acid (Zometa) was added to adjuvant chemotherapy and hormonal therapy, results of a” View full resource at medpagetoday.com
Most Recently Shared on December 10, 2010 at 12:53 am By:
SABCS: Bone Drug Fails to Stop Breast Cancer (CME/CE) http://bit.ly/hpLCa6
Advertisement
